Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Share :

ASCO GI 2023

19 - 21 Jan 2023
San Francisco, United States of America

Palliative radiotherapy for symptomatic hepatocellular carcinoma improves survival in HCC or liver metastases

Prof Laura Dawson - University of Toronto, Toronto, Canada
Palliative radiotherapy for symptomatic hepatocellular carcinoma improves survival in HCC or liver metastases ( Prof Laura Dawson - University of Toronto, Toronto, Canada )
7 Feb 2023

Trifluridine/tipiracil plus bevacizumab improves OS in mCRC

Dr Josep Tabernero - Vall d’Hebron University Hospital, Barcelona, Spain
Trifluridine/tipiracil plus bevacizumab improves OS in mCRC ( Dr Josep Tabernero - Vall d’Hebron University Hospital, Barcelona, Spain )
7 Feb 2023

Stereotactic body radiation therapy (SBRT) followed by sorafenib in HCC improves OS

Prof Laura Dawson - University of Toronto, Toronto, Canada
Stereotactic body radiation therapy (SBRT) followed by sorafenib in HCC improves OS ( Prof Laura Dawson - University of Toronto, Toronto, Canada )
7 Feb 2023

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer

Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )
26 Jan 2023

HER-Vaxx is safe and provides clinical benefit over standard of care chemo for patients with HER2-overexpressing gastric cancer

Dr Tanuj Chawla and Dr Giovanni Selvaggi
HER-Vaxx is safe and provides clinical benefit over standard of care chemo for patients with HER2-overexpressing gastric cancer ( Dr Tanuj Chawla and Dr Giovanni Selvaggi )
25 Jan 2023

Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
25 Jan 2023

Kinetics of postop circulating cell-free DNA and impact on MRD detection rates in resected stage I-III colorectal cancer

Dr Stacey Cohen - Fred Hutchinson Cancer Center, Washington, USA
Kinetics of postop circulating cell-free DNA and impact on MRD detection rates in resected stage I-III colorectal cancer ( Dr Stacey Cohen - Fred Hutchinson Cancer Center, Washington, USA )
25 Jan 2023

OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not compromise the chance of cure

Prof Arthur Sun Myint - Clatterbridge Cancer Centre, Clatterbridge, UK
OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not compromise the chance of cure ( Prof Arthur Sun Myint - Clatterbridge Cancer Centre, Clatterbridge, UK )
25 Jan 2023

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC

Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan
NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )
25 Jan 2023